

PEOPLE

Dick Anderson has been appointed president and chief operating officer of NeoRx (Seattle, WA). Mr. Anderson joined the company in 1997 as senior vice president and chief financial officer, and has been senior vice president, finance and operations since January 1998.

AxCel Biosciences (Princeton, NJ), a wholly owned subsidiary of Cytogen, has appointed **Brian Bullard** vice president and chief information officer. Previously, Mr. Bullard was in charge of scientific and market data valuation in conjunction with Perkin-Elmer's bioinformatics software platforms.

GalaGen (Arden Hills, MN), a nutraceutical products company, has announced that **Henry J. Cardello** has been appointed president and a member of the board of directors. Mr. Cardello is the former president of Sunkist Soft Drinks, a unit of Cadbury Schweppes.

Hyseq (Sunnyvale, CA) has promoted **Radoje T. Drmanac** to the newly created position of chief scientific officer. Dr. Drmanac previously held the position of senior vice president of research. Hyseq also announced the appointment of **Henryk Cudny** to director of protein purification. Dr. Cudny was most recently director of process development and manufacturing at Celtrix Pharmaceuticals.

Theodore H. Heinrichs has been appointed to the board of directors of Maxim Pharmaceuticals (San Diego, CA). Mr. Heinrichs served as general partner of Hambrecht & Quist Life Science Venture from 1985 to 1997. Also, Maxim announced the appointment of **Ram B. Rastogi** as vice president, clinical affairs. Dr. Rastogi most recently served as vice president, product development (global) at PPD Pharmaco.

Chiron (Emeryville, CA) has named **Robert G. Johnson, Jr.**, vice president of pharmacology and preclinical affairs. Before Chiron, Dr. Johnson served as director of pharmacology at the Merck Research Laboratories.

Sequenom (San Diego, CA) has announced that **Daniel Little** has been named director, East Coast operations, and that he will establish and manage Sequenom's East Coast collaboration and customer support activities from a new office in Boston, Massachusetts. Dr. Little was most recently the technology expert in the business development group at Sequenom. He joined the company in 1995.

Andrew Lyall has been named chief information officer for Oxford GlycoSciences

(Oxford, UK), with responsibility for leading the company's bioinformatics activities. Dr. Lyall joins OGS from Glaxo Wellcome, where he served as head of advanced technology and informatics.

Elan Corp. (Dublin, Ireland) has announced the appointment of **Kieran McGowan** to its board of directors. Mr. McGowan is retiring as chief executive of IDA Ireland, the government agency that encourages foreign enterprises to establish or expand in Ireland. He is also a director of CRH plc, Enterprise Ireland, The Irish Management Institute, and Ireland's National Lottery.

Affymetrix (Santa Clara, CA) has announced the promotion of **Richard P. Rava** to the newly created position of senior vice president and chief technology officer. Dr. Rava previously held the position of senior vice president, operations and technology.

Millennium Pharmaceuticals (Cambridge, MA) has named **Kevin Starr** to the position of chief financial officer. Most recently he served as the vice president, finance of Millennium BioTherapeutics, a majority-owned subsidiary of Millennium. The company also announced the appointments of three vice presidents: **Sandra DiCesare** to vice president, information systems, **Vincent Miles** to vice president, business and technology management, and **Kazumi Shiosaki** to vice president, drug discovery.

James Tobin has resigned from his position as president and CEO of Biogen (Cambridge, MA). To replace him, Biogen has appointed **James C. Mullen** president and chief operating officer, and **James Vincent**



James C. Mullen

CEO. Mr. Mullen joined Biogen in 1989 as director, facilities and engineering, and was most recently vice president, international. Mr. Vincent, who will remain as chairman of Biogen's board, previously served as president from 1985 to 1994 and as chief executive from 1985 to 1997.

Joseph C. Scodari, president and COO of Centocor (Malvern, PA), has been elected to the company's board of directors, increasing the number of board members to 10. Mr. Scodari was elected president and COO in 1997, after joining Centocor in 1996 as executive vice president and president of the pharmaceutical division.

1/3 Ad